Posted by Michael Wonder on 03 Dec 2025
Sangamo Therapeutics receives US FDA fast track designation for ST-503 for the treatment of small fibre neuropathy
2 December 2025 - Sangamo Therapeutics today announced that the US FDA has granted fast track designation to ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to small fibre neuropathy, a type of chronic neuropathic pain.
ST-503 is currently being evaluated in the Phase 1/2 STAND study, where patient recruitment and enrolment are in progress.
